普罗布考通过调控ABCA1、SR-BⅠ、ABCG5、ABCG8表达及抗炎作用抑制高胆固醇血症兔动脉粥样硬化（英文）

发布时间：2018-06-23 06:20

  本文选题：普罗布考 + 动脉粥样硬化　； 参考：《生物化学与生物物理进展》2015年09期

【摘要】：作为一种有效的降脂药物,普罗布考能够降低血浆高密度脂蛋白胆固醇(HDL-C)水平并抑制动脉粥样硬化,但其机制尚未完全阐明.本研究的目的旨在进一步阐明普罗布考降脂及抗动脉粥样硬化的机理.将新西兰白兔随机分为4组:正常饮食组、正常饮食+普罗布考组、高脂饮食组(HFD组)、高脂饮食+普罗布考组(HFD+P组).结果显示,处理7周后,与HFD组比较,H FD+P组动脉粥样硬化病变程度、肝脏脂质蓄积明显减轻,血浆甘油三脂、总胆固醇、低密度脂蛋白胆固醇及HDL-C水平降低,肝脏中清道夫受体-BⅠ(SR-BⅠ)以及肝脏与小肠中三磷酸腺苷结合盒转运体(ABC)G5(ABCG5)、ABCG8表达上调,肝脏中A BCA1表达下调,主动脉弓与血浆肿瘤坏死因子α、白介素1、白介素6、单核趋化蛋白1水平降低.这些结果表明普罗布考的抗动脉粥样硬化作用可能与其调控A BCA1、SR-BⅠ、ABCG5、ABCG8表达及抑制促炎介质的分泌有关.
[Abstract]:As an effective lipid lowering drug, Probucol can reduce plasma high density lipoprotein cholesterol (HDL-C) and inhibit atherosclerosis, but its mechanism has not been fully elucidated. The aim of this study was to further elucidate the mechanism of probucol's lipid lowering and anti-atherosclerosis. New Zealand white rabbits were randomly divided into 4 groups: normal diet group, normal diet probucol group, high fat diet group (HFD group) and high fat diet probucol group (HFD group). The results showed that compared with HFD group, the degree of atherosclerosis, hepatic lipid accumulation, plasma triglyceride, total cholesterol, low density lipoprotein cholesterol and HDL-C levels were significantly decreased in H FD P group after 7 weeks of treatment. The expression of scavenger receptor -B 鈪，

本文编号：2056176